


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A composition of matter of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently randomized EPO-mimetic antagonist peptide sequences of pharmacologically active peptides;

L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither X^1 nor X^2 is a native protein.


2. (original) The composition of matter of Claim 1 of the formulae




or



3. (original) The composition of matter of Claim 1 of the formula



4. (original) The composition of matter of Claim 1 of the formula



5. (original) The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.

6. (original) The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.

7. (original) The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

8. (canceled).

9. (canceled).
10. (canceled).
11. (canceled).
12. (canceled).
13. (currently amended) The composition of matter of Claim ~~12~~1 wherein the EPO mimetic peptide sequence is selected from Table 5.
14. (currently amended) The composition of matter of Claim ~~12~~1 wherein F¹ comprises the sequence of SEQ ID NO: 2.
15. (currently amended) The composition of matter of Claim ~~12~~1 comprising a sequence selected from SEQ ID NOS: 83, 84, 85, 124, 419, 420, 421, and 41.
16. The composition of matter of Claim ~~12~~1 comprising a sequence selected from SEQ ID NOS: 339 and 340.

Claims 17 - 51 (canceled).